T. Rowe Price Health SciencesPRHSX

Morningstar Rating

Fund Research and Analysis

by Christopher Davis

T. Rowe Price Health Sciences may now play a similar game as its rivals, but it does it better.

When manager Kris Jenner took charge of this fund in 2000, he employed an approach like few of his competitors. He focused nearly exclusively on pharmaceutical Read more

Kudos

Solid long-term record.

Below-average expenses.

Experienced manager backed by strong analyst research. Read more

Risks

The fund's smaller-cap focus means its has less exposure to health-care bellwethers than its peers, which can lead to above-average losses in down markets. Read more

Strategy

Manager Kris Jenner has spread his wings in recent years, broadening his portfolio to include all major health-care subsectors. Still, Jenner emphasizes mid- and small-cap stocks to a greater extent Read more

Management

Kris Jenner, a physician by training, has been at the fund's helm since February 2000. Before that, he served as T. Rowe Price's biotechnology analyst for two years. Four analysts support Jenner in running the portfolio. Read more

Inside Scoop

After beginning the early 2000s as one its category's more-adventuresome options, this fund has moderated its ways. It hasn't lost its bold streak entirely, as smaller-cap Read more

First Name

Last Name

Email Address

Zip Code

Create Password

Verify Password

(6-15 characters; case sensitive)

What is your occupation or job title?

Select...

Your registration indicates agreement to the terms of use.

Dodge & Cox: Health Care Now More Attractive
Watch more